Trials / Completed
CompletedNCT00383422
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arzoxifene | 20 mg, oral, tablet, once a day for 52 weeks |
| DRUG | Raloxifene | 60 mg, oral, tablet, once a day for 52 weeks |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2006-10-03
- Last updated
- 2010-01-28
Locations
21 sites across 8 countries: United States, Argentina, Australia, Canada, France, Italy, Spain, Taiwan
Source: ClinicalTrials.gov record NCT00383422. Inclusion in this directory is not an endorsement.